Last Updated: 08 Nov 2024
Executive Summary
Altimmune Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company has a market capitalization of $530.19 million and trades on the NASDAQ exchange.
Company Overview
Altimmune's lead product candidate is AdCOVID, an intranasal COVID-19 vaccine. The company is also developing other intranasal vaccines for respiratory syncytial virus (RSV) and influenza. In addition, Altimmune is developing HepTcell, a cell therapy for chronic hepatitis B virus (HBV) infection.
Fundamental Analysis
Altimmune's financial performance has been mixed in recent quarters. The company reported a net loss of $96.9 million in the first half of 2023, compared to a net loss of $83.4 million in the first half of 2022. Revenue increased from $287,000 to $409,000 over the same period.
Altimmune's balance sheet is relatively strong, with $134.6 million in cash and equivalents as of June 30, 2023. The company also has a number of strategic partnerships with larger pharmaceutical companies, which could provide additional funding in the future.
Technical Analysis
ALT's stock price has been trending lower in recent months. The stock is currently trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is also below 50, indicating that the stock is oversold.
Short Term Outlook
The short-term outlook for ALT is mixed. The company's financial performance has been improving, but the stock price has been trending lower. The stock could continue to decline in the near term, but it could also rebound if the company reports positive news on its clinical trials.
Long Term Outlook
The long-term outlook for ALT is more positive. The company's pipeline of products has the potential to generate significant revenue in the future. If Altimmune can successfully commercialize its intranasal vaccines and HepTcell, the stock could be a good long-term investment.
Analyst Recommendations
Analysts are generally positive on ALT. The average analyst rating is "buy," with a price target of $20.57.
